MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Monoaminergic biomarkers of cognitive decline in Parkinson’s disease and Lewy body dementia

S. van der Zee, Y. Vermeiren, T. Aerts, D. van Dam, M.J. Gerritsen, J.M. Spikman, T. van Laar, P.P. de Deyn (Groningen, Netherlands)

Meeting: 2016 International Congress

Abstract Number: 1425

Keywords: Cognitive dysfunction, Dementia with Lewy bodies (DLB)

Session Information

Date: Wednesday, June 22, 2016

Session Title: Cognition and Psychiatry

Session Time: 12:00pm-1:30pm

Objective: The objective of this study was the identification of biochemical markers of cognitive impairment in Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) by focusing on cerebrospinal fluid (CSF) and serum levels of various monoaminergic neurotransmitters across different stages of cognitive decline.

Methods: The study population comprised 154 subjects in total, of which 43 healthy control subjects, 28 patients with PD, 27 patients with PD and mild cognitive impairment (PD-MCI), 18 patients with PD dementia (PDD), and, 38 patients with DLB. Matched serum and CSF levels of a variety of eight monoamines and metabolites were analyzed applying RP-HPLC-ECD, i.e. dopamine (DA), serotonin (5-HT), (nor)adrenaline ((N)A) and their respective metabolites, i.e. 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), 5-hydroxy-3-indoleacetic acid (5-HIAA), and, 3-methoxy-4-hydroxyphenylglycol (MHPG). Furthermore, MMSE scores were obtained as a parameter of cognitive performance and the administered psychotropic medication was documented.

Results: CSF and serum levels of both NA and MHPG were found to be significantly higher in patients with PD compared to healthy control subjects. In addition, in PD patients, CSF MHPG levels were higher in patients with PDD compared to cognitively normal PD patients. Furthermore, we observed higher CSF and serum 5-HIAA levels in healthy controls compared to all PD groups and DLB patients. As for the patient groups, CSF 5-HIAA levels were lower especially in patients with cognitive decline. More specifically, CSF 5-HIAA levels of PD-MCI, PDD and DLB patients differed significantly from those of healthy controls as well as PD patients without cognitive impairment. Finally, serum DA levels were significantly lower in DLB patients compared to controls whereas CSF and serum levels of HVA and DOPAC had the highest values for PD groups.

Conclusions: Monoaminergic neurotransmitter and metabolite levels in serum and CSF not only differed between healthy controls, PD and DLB patients, but also across different stages of cognitive impairment in PD. Our data suggests an important correlation between cognitive deterioration in PD and a dysfunctioning of especially the noradrenergic and serotonergic neurotransmission. This study therefore hypothesizes that these monoamines and metabolites could prove to be potential biomarkers for the cognitive decline in PD and DLB.

To cite this abstract in AMA style:

S. van der Zee, Y. Vermeiren, T. Aerts, D. van Dam, M.J. Gerritsen, J.M. Spikman, T. van Laar, P.P. de Deyn. Monoaminergic biomarkers of cognitive decline in Parkinson’s disease and Lewy body dementia [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/monoaminergic-biomarkers-of-cognitive-decline-in-parkinsons-disease-and-lewy-body-dementia/. Accessed July 6, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/monoaminergic-biomarkers-of-cognitive-decline-in-parkinsons-disease-and-lewy-body-dementia/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley